As 2025 begins, we reflect on an incredible 2024—a year of progress, collaboration, and milestones in rare disease diagnostics. Your commitment to advancing genetic testing inspires us at 3billion. Together, we've transformed lives, bringing hope to patients and families facing rare diseases.
Thank you for your trust, partnership, and impact. Here's to creating even more breakthroughs together!

3billion’s
2024 in Numbers

*All figures represent cumulative data as of 2024.

11+

Industry Awards
Won

Published
Papers

114

Patients
for Filing

38

Clinicians and
Researchers Served

1,600

Genomic Data
Processed

70,000

Variants
Registered

5,800

Patients
Tested

62,000

Partnered
Institutions

700

Diagnostic
Rate

32%

2024 Milestones
and Highlights

FEB

Rare Disease Day Event ↗

MAR

Publication of 3ASC Journal ↗

JUL

Participation in the Korean Genetic Diagnosis Support Project

3B-GENOME & 3B-EXOME’s TAT Reduced to 5 weeks ↗

OCT

ISO/IEC 27001:2022 Certification Secured ↗

GEBRA SaaS Beta Testing Launches

3billion 8-Year Anniversary Celebration

NOV

Partnership with Korea Rare Disease Foundation ↗

Public Listing on KOSDAQ ↗

DEC

New Office Expansion

3billion’s Year of
Global Footprints

Empowering Rare Disease Patients with Insights 
from 70,000+ Genomic Data Worldwide

In Mexico

At ACMG, Canada

In Malaysia

At ESHG, Germany

In Chile

in Saudi Arabia

In Eastern Europe

in Egypt

at AMGH, Mexico

3billion’s2024 in Numbers

11+

Industry Awards Won

Published Papers

114

Patients for Filing

38

Clinicians and Researchers Served